Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain.

Wojcik J, Hantschel O, Grebien F, Kaupe I, Bennett KL, Barkinge J, Jones RB, Koide A, Superti-Furga G, Koide S.

Nat Struct Mol Biol. 2010 Apr;17(4):519-27. doi: 10.1038/nsmb.1793. Epub 2010 Mar 28.

2.

Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface.

Wojcik J, Lamontanara AJ, Grabe G, Koide A, Akin L, Gerig B, Hantschel O, Koide S.

J Biol Chem. 2016 Apr 15;291(16):8836-47. doi: 10.1074/jbc.M115.707901. Epub 2016 Feb 24.

3.

Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains.

Sha F, Gencer EB, Georgeon S, Koide A, Yasui N, Koide S, Hantschel O.

Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):14924-9. doi: 10.1073/pnas.1303640110. Epub 2013 Aug 26.

4.

Selective Targeting of SH2 Domain-Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies.

Kükenshöner T, Schmit NE, Bouda E, Sha F, Pojer F, Koide A, Seeliger M, Koide S, Hantschel O.

J Mol Biol. 2017 May 5;429(9):1364-1380. doi: 10.1016/j.jmb.2017.03.023. Epub 2017 Mar 25.

5.

Intramolecular interactions of the regulatory domains of the Bcr-Abl kinase reveal a novel control mechanism.

Nam HJ, Haser WG, Roberts TM, Frederick CA.

Structure. 1996 Sep 15;4(9):1105-14.

6.

Iterative tyrosine phosphorylation controls non-canonical domain utilization in Crk.

Sriram G, Jankowski W, Kasikara C, Reichman C, Saleh T, Nguyen KQ, Li J, Hornbeck P, Machida K, Liu T, Li H, Kalodimos CG, Birge RB.

Oncogene. 2015 Aug 6;34(32):4260-9. doi: 10.1038/onc.2014.361. Epub 2014 Nov 10.

7.

A limited set of SH2 domains binds BCR through a high-affinity phosphotyrosine-independent interaction.

Muller AJ, Pendergast AM, Havlik MH, Puil L, Pawson T, Witte ON.

Mol Cell Biol. 1992 Nov;12(11):5087-93.

8.

Crystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activity.

Lorenz S, Deng P, Hantschel O, Superti-Furga G, Kuriyan J.

Biochem J. 2015 Jun 1;468(2):283-91. doi: 10.1042/BJ20141492.

PMID:
25779001
9.

En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase.

Muller AJ, Pendergast AM, Parmar K, Havlik MH, Rosenberg N, Witte ON.

Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3457-61.

10.

The SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling activation loop accessibility.

Lamontanara AJ, Georgeon S, Tria G, Svergun DI, Hantschel O.

Nat Commun. 2014 Nov 17;5:5470. doi: 10.1038/ncomms6470.

PMID:
25399951
11.

Direct analysis of the binding of the abl Src homology 2 domain to the activated epidermal growth factor receptor.

Zhu G, Decker SJ, Mayer BJ, Saltiel AR.

J Biol Chem. 1993 Jan 25;268(3):1775-9.

PMID:
7678409
12.
13.
14.

The Abl SH2-kinase linker naturally adopts a conformation competent for SH3 domain binding.

Chen S, Brier S, Smithgall TE, Engen JR.

Protein Sci. 2007 Apr;16(4):572-81. Epub 2007 Feb 27.

15.

Tyrosine phosphorylation in the SH3 domain disrupts negative regulatory interactions within the c-Abl kinase core.

Chen S, O'Reilly LP, Smithgall TE, Engen JR.

J Mol Biol. 2008 Nov 7;383(2):414-23. doi: 10.1016/j.jmb.2008.08.040. Epub 2008 Aug 23.

16.

Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck.

Eck MJ, Shoelson SE, Harrison SC.

Nature. 1993 Mar 4;362(6415):87-91.

PMID:
7680435
17.

The solution structure of Abl SH3, and its relationship to SH2 in the SH(32) construct.

Gosser YQ, Zheng J, Overduin M, Mayer BJ, Cowburn D.

Structure. 1995 Oct 15;3(10):1075-86.

18.

Enhanced phosphorylation of Src family kinase substrates containing SH2 domain binding sites.

Pellicena P, Stowell KR, Miller WT.

J Biol Chem. 1998 Jun 19;273(25):15325-8.

19.

Temperature-sensitive transformation by an Abelson virus mutant encoding an altered SH2 domain.

Mainville CA, Parmar K, Unnikrishnan I, Gong L, Raffel GD, Rosenberg N.

J Virol. 2001 Feb;75(4):1816-23.

20.

Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.

Ling X, Ma G, Sun T, Liu J, Arlinghaus RB.

Cancer Res. 2003 Jan 15;63(2):298-303.

Supplemental Content

Support Center